Literature DB >> 32145242

The link "Cancer and autoimmune diseases" in the light of microbiota: Evidence of a potential culprit.

Elena Niccolai1, Federico Boem2, Giacomo Emmi3, Amedeo Amedei4.   

Abstract

Evidence establishes that chronic inflammation and autoimmunity are associated with cancer development and patients with a primary malignancy may develop autoimmune-like diseases. Despite immune dysregulation is a common feature of both cancer and autoimmune diseases, precise mechanisms underlying this susceptibility are not clarified and different hypotheses have been proposed, starting from genetic and environmental common features, to intrinsic properties of immune system. Moreover, as the development and use of immunomodulatory therapies for cancer and autoimmune diseases are increasing, the elucidation of this relationship must be investigated in order to offer the best and most secure therapeutic options. The microbiota could represent a potential link between autoimmune diseases and cancer. The immunomodulation role of microbiota is widely recognized and under eubiosis, it orchestrates both the innate and adaptive response of immunity, in order to discriminate and modulate the immune response itself in the most appropriate way. Therefore, a dysbiotic status can alter the immune tonus rendering the host prone to exogenous or endogenous infections, breaking the tolerance against self-components and activating the immune responses in an excessive (i.e. chronic inflammation) or deficient way, favoring the onset of neoplastic and autoimmune diseases.
Copyright © 2020 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adaptive immune system; Autoimmune diseases; Cancer; Innate immune system; Microbiota

Mesh:

Year:  2020        PMID: 32145242     DOI: 10.1016/j.imlet.2020.03.001

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  4 in total

Review 1.  PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases.

Authors:  Ke Zhang; Xiangyi Kong; Yuan Li; Zhongzhao Wang; Lin Zhang; Lixue Xuan
Journal:  Front Pharmacol       Date:  2022-03-18       Impact factor: 5.810

2.  Gut Microbiota and Associated Mucosal Immune Response in Eosinophilic Granulomatosis with Polyangiitis (EGPA).

Authors:  Elena Niccolai; Alessandra Bettiol; Simone Baldi; Elena Silvestri; Leandro Di Gloria; Federica Bello; Giulia Nannini; Federica Ricci; Maria Nicastro; Matteo Ramazzotti; Augusto Vaglio; Gianluca Bartolucci; Giacomo Emmi; Amedeo Amedei; Domenico Prisco
Journal:  Biomedicines       Date:  2022-05-24

3.  Meroterpenoids from the Brown Alga Cystoseira usneoides as Potential Anti-Inflammatory and Lung Anticancer Agents.

Authors:  Hanaa Zbakh; Eva Zubía; Carolina de Los Reyes; José M Calderón-Montaño; Miguel López-Lázaro; Virginia Motilva
Journal:  Mar Drugs       Date:  2020-04-11       Impact factor: 5.118

4.  Diterpenoids from the Brown Alga Rugulopteryx okamurae and Their Anti-Inflammatory Activity.

Authors:  Belén Cuevas; Ana I Arroba; Carolina de Los Reyes; Laura Gómez-Jaramillo; M Carmen González-Montelongo; Eva Zubía
Journal:  Mar Drugs       Date:  2021-11-27       Impact factor: 5.118

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.